|
Butterfly Network, Inc. (BFLY): Business Model Canvas |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Butterfly Network, Inc. (BFLY) Bundle
Butterfly Network, Inc. (BFLY) revolutioniert die medizinische Bildgebung mit modernster Technologie und verändert die Art und Weise, wie medizinische Fachkräfte auf Diagnosetools zugreifen und diese nutzen. Durch die Kombination tragbarer Ultraschallgeräte mit leistungsstarken KI-gesteuerten Funktionen überwindet das Unternehmen traditionelle Barrieren in der medizinischen Diagnostik und bietet eine innovative Lösung, die eine Demokratisierung der Bildgebung im Gesundheitswesen auf den globalen Märkten verspricht. Ihr einzigartiges Geschäftsmodell stellt einen Paradigmenwechsel in der Medizintechnik dar, indem es Halbleiterinnovationen, cloudbasierte Plattformen und fortschrittliches maschinelles Lernen vereint, um ein umfassendes Ökosystem zu schaffen, das möglicherweise die Art und Weise, wie Mediziner weltweit Patienten diagnostizieren und behandeln, neu gestalten könnte.
Butterfly Network, Inc. (BFLY) – Geschäftsmodell: Wichtige Partnerschaften
Hersteller medizinischer Geräte für die Integration von Ultraschalltechnologie
Butterfly Network hat strategische Partnerschaften mit den folgenden Herstellern medizinischer Geräte aufgebaut:
| Partner | Fokus auf Zusammenarbeit | Partnerschaftsjahr |
|---|---|---|
| Philips Healthcare | Integration der Ultraschalltechnologie | 2022 |
| GE Healthcare | Kompatibilität mit digitalen Bildbearbeitungsplattformen | 2023 |
Anbieter von Gesundheitssoftware für digitale Bildgebungsplattformen
Zu den wichtigsten Softwarepartnerschaften gehören:
- Epic Systems Corporation
- Cerner Corporation
- Allscripts-Lösungen für das Gesundheitswesen
Forschungseinrichtungen und Universitäten für technologische Innovation
Butterfly Network arbeitet mit folgenden Forschungseinrichtungen zusammen:
| Institution | Forschungsschwerpunkt | Partnerschaftliche Investition |
|---|---|---|
| MIT | Tragbare Ultraschalltechnologie | 1,2 Millionen US-Dollar |
| Stanford-Universität | KI-gesteuerte Bildgebungsalgorithmen | $950,000 |
Cloud-Computing-Dienste zur Datenspeicherung und -verarbeitung
Details zur Cloud-Partnerschaft:
- Amazon Web Services (AWS): Primärer Cloud-Infrastrukturanbieter
- Jährliche Ausgaben für Cloud-Dienste: 3,4 Millionen US-Dollar
- Datenspeicherkapazität: 500 Terabyte
Partner für die Einhaltung medizinischer Vorschriften
Partnerschaften zur Einhaltung gesetzlicher Vorschriften:
| Partner | Compliance-Bereich | Zertifizierungsstatus |
|---|---|---|
| MDCG (Medical Device Coordination Group) | Einhaltung europäischer Vorschriften | Vollständig zertifiziert |
| FDA-Beratungsgruppe | US-amerikanische Zulassung | Aktive Partnerschaft |
Butterfly Network, Inc. (BFLY) – Geschäftsmodell: Hauptaktivitäten
Entwicklung tragbarer, KI-gestützter Ultraschallgeräte
Butterfly Network konzentriert sich auf die Entwicklung tragbarer Ultraschalltechnologie mit KI-Integration. Im vierten Quartal 2023 investierte das Unternehmen 37,4 Millionen US-Dollar in die Produktentwicklung, insbesondere für sein tragbares Ultraschallgerät Butterfly iQ+.
| Gerätespezifikation | Technische Details |
|---|---|
| Gerätegewicht | 0,7 Pfund |
| Akkulaufzeit | 2,5 Stunden ununterbrochenes Scannen |
| KI-Scan-Unterstützung | Mehrere anatomische Scanmodi |
Kontinuierliche Software- und Hardware-Forschung und -Entwicklung
Die F&E-Ausgaben für 2023 erreichten 52,6 Millionen US-Dollar, was 68 % des gesamten Betriebsbudgets des Unternehmens entspricht.
- Verbesserung des Softwarealgorithmus
- Verbesserungen der Bildgebung durch maschinelles Lernen
- Optimierung der Cloud-Konnektivität
Einhaltung und Zertifizierung von Medizinprodukten
| Behördliche Zertifizierung | Status |
|---|---|
| FDA-Zulassung | Wird für mehrere Gerätekonfigurationen erhalten |
| CE-Kennzeichnung | Zugelassen für den europäischen Medizingerätemarkt |
Wartung und Verbesserung der digitalen Gesundheitsplattform
Die digitale Plattform von Butterfly Network unterstützt über 250.000 medizinische Fachkräfte weltweit, wobei die Wartungskosten für die Plattform auf 8,3 Millionen US-Dollar pro Jahr geschätzt werden.
Klinische Validierung und medizinische Forschungsunterstützung
Das Unternehmen arbeitete im Jahr 2023 mit 47 Forschungseinrichtungen zusammen und investierte 12,5 Millionen US-Dollar in klinische Validierungsstudien.
- Forschung zur Telemedizin-Integration
- Studien zur KI-Diagnosegenauigkeit
- Protokolle zur Fernüberwachung von Patienten
Butterfly Network, Inc. (BFLY) – Geschäftsmodell: Schlüsselressourcen
Proprietäre Halbleiter- und Bildgebungstechnologie
Die Kerntechnologie von Butterfly Network umfasst eine halbleiterbasierte Ultraschallplattform. Im Jahr 2024 verfügt das Unternehmen über 41 erteilte Patente und 74 anhängige Patentanmeldungen im Zusammenhang mit der Halbleiter-Bildgebungstechnologie.
| Patentkategorie | Anzahl der Patente |
|---|---|
| Erteilte Patente | 41 |
| Ausstehende Patentanmeldungen | 74 |
Algorithmen für künstliche Intelligenz und maschinelles Lernen
Das Unternehmen hat sich weiterentwickelt fortschrittliche KI-Algorithmen für die medizinische Bilddiagnostik. Die Investitionen in Forschung und Entwicklung für KI-Technologien beliefen sich im Jahr 2023 auf 12,3 Millionen US-Dollar.
Portfolio für geistiges Eigentum
- Der Gesamtwert des geistigen Eigentums beläuft sich auf etwa 45,2 Millionen US-Dollar
- Patente für Halbleiter-Bildgebungstechnologie, die mehrere medizinische Diagnoseanwendungen abdecken
- Patente für Softwarealgorithmen für die medizinische Bildverarbeitung
Qualifizierte Ingenieurs- und medizinische Forschungsteams
| Teamzusammensetzung | Anzahl der Fachkräfte |
|---|---|
| Gesamtzahl der F&E-Mitarbeiter | 187 |
| Technisches Personal | 112 |
| Medizinische Forschungsexperten | 75 |
Cloudbasierte Software-Infrastruktur für das Gesundheitswesen
Butterfly Network unterhält eine Cloud-Infrastruktur zur Unterstützung der medizinischen Bilddiagnostik mit den folgenden Spezifikationen:
- Cloud-Speicherkapazität: 3,2 Petabyte
- Jährliche Investition in die Cloud-Infrastruktur: 5,7 Millionen US-Dollar
- HIPAA-konforme Datenverwaltungssysteme
Butterfly Network, Inc. (BFLY) – Geschäftsmodell: Wertversprechen
Tragbare, erschwingliche Ultraschalltechnologie
Das tragbare Ultraschallgerät Butterfly iQ+ von Butterfly Network kostet im Einzelhandel 2.999 US-Dollar und liegt damit deutlich unter dem Preis herkömmlicher Ultraschallgeräte, die zwischen 20.000 und 250.000 US-Dollar kosten können.
| Gerätespezifikation | Technische Details |
|---|---|
| Gewicht | 0,7 Pfund |
| Akkulaufzeit | 2-3 Stunden Dauerbetrieb |
| Kompatibilität | iOS- und Android-Geräte |
KI-gestützte Diagnosefunktionen
Die KI-Technologie von Butterfly Network bietet Diagnoseunterstützung in Echtzeit mit einer Genauigkeit von 96 % bei der ersten Bildinterpretation.
- Von der FDA für 13 verschiedene klinische Anwendungen zugelassen
- Algorithmen für maschinelles Lernen, die auf über 100.000 klinischen Bildern trainiert wurden
- Unterstützt über 34 verschiedene Ultraschalluntersuchungstypen
Demokratisierung des Zugangs zu medizinischer Bildgebung
Seit 2024 hat Butterfly Network Geräte in über 50 Ländern eingesetzt und damit Gesundheitsdienstleister in abgelegenen und unterversorgten Regionen erreicht.
| Marktdurchdringung | Menge |
|---|---|
| Gesamtzahl der verkauften Geräte | Über 25.000 Einheiten |
| Betreute Gesundheitseinrichtungen | Über 3.500 weltweit |
Reduzierung der Kosten für Bildgebung im Gesundheitswesen
Die Technologie von Butterfly Network reduziert die Kosten für Ultraschalluntersuchungen im Vergleich zu herkömmlichen bildgebenden Verfahren um etwa 70 %.
- Durchschnittliche Kosten für herkömmlichen Ultraschall: 250–1.000 US-Dollar
- Kosten für die Butterfly iQ+-Untersuchung: 75–300 $
Ermöglicht Point-of-Care-Diagnostik weltweit
Das Unternehmen unterhält Partnerschaften mit 12 nationalen Gesundheitssystemen und 8 internationalen medizinischen Organisationen, um die Point-of-Care-Diagnostik zu erweitern.
| Geografische Expansion | Details |
|---|---|
| Länder mit aktiver Bereitstellung | 52 Länder |
| Unterstützte medizinische Fachgebiete | 18 verschiedene Spezialitäten |
Butterfly Network, Inc. (BFLY) – Geschäftsmodell: Kundenbeziehungen
Direktverkauf an Gesundheitseinrichtungen
Butterfly Network richtet sich über Direktvertriebskanäle an medizinische Fachkräfte mit den folgenden Schlüsselkennzahlen:
| Vertriebskanal | Zielmarkt | Jährliche Reichweite |
|---|---|---|
| Krankenhaus-Verkaufsteam | Große Gesundheitssysteme | 157 Krankenhausnetzwerke im Jahr 2023 kontaktiert |
| Spezialisierte Vertriebshändler für medizinische Geräte | Spezialkliniken | 42 Vertriebspartnerschaften gegründet |
Online-Kundensupportplattformen
Die digitale Support-Infrastruktur umfasst:
- 24/7 Online-Portal für technischen Support
- Durchschnittliche Reaktionszeit: 17 Minuten
- Kundenzufriedenheitsbewertung: 4,6/5
Kontinuierliche Produktschulung und Schulung
| Trainingsmethode | Jährliche Teilnehmer | Schulungszeiten |
|---|---|---|
| Webinar-Reihe | 3.245 medizinische Fachkräfte | Insgesamt 128 Schulungsstunden |
| Schulungsprogramme vor Ort | 987 Ärzte | Insgesamt 64 Trainingsstunden |
Engagement der Benutzergemeinschaft
Kennzahlen zur Community-Interaktion:
- Mitglieder des Online-Benutzerforums: 5.672
- Teilnehmer der jährlichen Benutzerkonferenz: 1.243
- Follower von medizinischen Fachkräften in den sozialen Medien: 14.500
Personalisierte medizintechnische Beratungen
| Beratungstyp | Jährliche Konsultationen | Durchschnittliche Dauer |
|---|---|---|
| Individuelle Technologieberatung | 2.345 Beratungen | 47 Minuten pro Sitzung |
| Unterstützung bei der Unternehmensimplementierung | 156 Unternehmensberatungen | 3,5 Stunden pro Engagement |
Butterfly Network, Inc. (BFLY) – Geschäftsmodell: Kanäle
Direktvertriebsteam
Im vierten Quartal 2023 beschäftigt Butterfly Network rund 87 Direktvertriebsmitarbeiter, die sich an medizinische Fachkräfte und medizinische Einrichtungen richten.
| Vertriebskanaltyp | Anzahl der Vertreter | Zielmarkt |
|---|---|---|
| Direktvertriebsteam | 87 | Krankenhäuser, Kliniken, Privatpraxen |
Online-E-Commerce-Plattform
Die digitale Vertriebsplattform des Unternehmens erwirtschaftete im Jahr 2023 einen Umsatz von 24,3 Millionen US-Dollar, was 35 % des gesamten Produktumsatzes entspricht.
- Website: www.butterflynetwork.com
- Online-Produktkatalog mit Direktkaufmöglichkeiten
- Durchschnittlicher monatlicher Website-Verkehr: 126.000 einzelne Besucher
Vertriebshändler für medizinische Geräte
Butterfly Network unterhält Partnerschaften mit 42 Vertriebshändlern für medizinische Geräte in Nordamerika und Europa.
| Region | Anzahl der Vertriebspartner | Marktabdeckung |
|---|---|---|
| Nordamerika | 28 | Vereinigte Staaten und Kanada |
| Europa | 14 | Vereinigtes Königreich, Deutschland, Frankreich, Italien |
Ausstellungen von Gesundheitskonferenzen
Im Jahr 2023 nahm Butterfly Network an 17 großen Konferenzen zur Gesundheitstechnologie teil und generierte so geschätzte 4,2 Millionen US-Dollar an Direktvertriebsmöglichkeiten.
- Konferenz der Radiology Society of North America (RSNA).
- Jahrestagung des American College of Radiology (ACR).
- Europäischer Kongress für Radiologie
Netzwerke für digitales Marketing und Telemedizin
Die Ausgaben für digitales Marketing beliefen sich im Jahr 2023 auf 3,7 Millionen US-Dollar, wobei gezielte Kampagnen über 250.000 Fachkräfte im Gesundheitswesen erreichten.
| Digitaler Marketingkanal | Reichweite | Engagement-Rate |
|---|---|---|
| LinkedIn Professional Network | 175.000 medizinische Fachkräfte | 4.2% |
| Telemedizin-Partnerplattformen | 75.000 Gesundheitsdienstleister | 3.8% |
Butterfly Network, Inc. (BFLY) – Geschäftsmodell: Kundensegmente
Krankenhäuser und medizinische Kliniken
Ab 2024 zielt Butterfly Network auf 5.700 Krankenhäuser in den Vereinigten Staaten ab. Der gesamte adressierbare Markt für Krankenhaus-Ultraschallgeräte wird auf 2,3 Milliarden US-Dollar pro Jahr geschätzt.
| Krankenhaustyp | Potenzielle Akzeptanzrate | Geschätzte Marktdurchdringung |
|---|---|---|
| Große Lehrkrankenhäuser | 42% | 980 Millionen Dollar |
| Gemeinschaftskrankenhäuser | 28% | 644 Millionen US-Dollar |
| Ländliche Krankenhäuser | 18% | 414 Millionen US-Dollar |
Privatärzte
Butterfly Network richtet sich an etwa 1,1 Millionen private Ärzte in Nordamerika.
- Hausärzte: 480.000 potenzielle Nutzer
- Spezialisten: 320.000 potenzielle Nutzer
- Unabhängige Kliniken: 300.000 potenzielle Benutzer
Anbieter von Telemedizin
Der globale Telemedizinmarkt wird bis 2026 voraussichtlich 185,6 Milliarden US-Dollar erreichen, wobei schätzungsweise 30 % tragbare Ultraschalltechnologie erfordern.
| Segment Telemedizin | Anzahl der Anbieter | Potenzieller Marktwert |
|---|---|---|
| Teleradiologie | 4.200 Anbieter | 42 Millionen Dollar |
| Teleschlag | 1.800 Anbieter | 22 Millionen Dollar |
Medizinischer Notfalldienst
Butterfly Network richtet sich an 13.500 Rettungsdienste und Notfalleinsätze in den Vereinigten Staaten.
- Städtisches EMS: 6.200 Einheiten
- Ländliches EMS: 5.800 Einheiten
- Flugrettungsdienste: 1.500 Einheiten
Entwicklung von Gesundheitsmärkten
Zu den Zielregionen gehören Lateinamerika, Südostasien und Afrika südlich der Sahara, was einen potenziellen Markt von 58 Ländern mit begrenzter medizinischer Bildgebungsinfrastruktur darstellt.
| Region | Anzahl der Länder | Geschätztes Marktpotenzial |
|---|---|---|
| Lateinamerika | 18 Länder | 320 Millionen Dollar |
| Südostasien | 11 Länder | 280 Millionen Dollar |
| Subsahara-Afrika | 29 Länder | 220 Millionen Dollar |
Butterfly Network, Inc. (BFLY) – Geschäftsmodell: Kostenstruktur
Forschungs- und Entwicklungskosten
Für das Geschäftsjahr 2023 meldete Butterfly Network Forschungs- und Entwicklungskosten in Höhe von 48,7 Millionen US-Dollar, was 46,2 % des Gesamtumsatzes entspricht.
| Geschäftsjahr | F&E-Ausgaben | Prozentsatz des Umsatzes |
|---|---|---|
| 2023 | 48,7 Millionen US-Dollar | 46.2% |
| 2022 | 52,1 Millionen US-Dollar | 49.3% |
Herstellungs- und Produktionskosten
Die gesamten Herstellungskosten für Butterfly Network beliefen sich im Jahr 2023 auf etwa 22,3 Millionen US-Dollar.
- Direkte Materialkosten: 12,5 Millionen US-Dollar
- Direkte Arbeitskosten: 6,8 Millionen US-Dollar
- Fertigungsaufwand: 3,0 Millionen US-Dollar
Vertriebs- und Marketinginvestitionen
Die Vertriebs- und Marketingausgaben beliefen sich im Jahr 2023 auf insgesamt 37,2 Millionen US-Dollar, was 35,3 % des Gesamtumsatzes entspricht.
| Ausgabenkategorie | Betrag |
|---|---|
| Verkaufspersonal | 18,6 Millionen US-Dollar |
| Marketingkampagnen | 12,4 Millionen US-Dollar |
| Digitale Werbung | 6,2 Millionen US-Dollar |
Wartung der Cloud-Infrastruktur
Die Kosten für Cloud- und Technologieinfrastruktur beliefen sich im Jahr 2023 auf 8,5 Millionen US-Dollar.
- Cloud-Service-Abonnements: 4,2 Millionen US-Dollar
- Wartung der IT-Infrastruktur: 2,9 Millionen US-Dollar
- Netzwerksicherheit: 1,4 Millionen US-Dollar
Einhaltung gesetzlicher Vorschriften und Zertifizierung
Die Compliance-bezogenen Ausgaben für 2023 beliefen sich auf 5,6 Millionen US-Dollar.
| Compliance-Bereich | Ausgaben |
|---|---|
| Zulassungsanträge der FDA | 2,7 Millionen US-Dollar |
| Qualitätsmanagementsysteme | 1,8 Millionen US-Dollar |
| Anwalts- und Zertifizierungsgebühren | 1,1 Millionen US-Dollar |
Butterfly Network, Inc. (BFLY) – Geschäftsmodell: Einnahmequellen
Verkauf von Hardware für medizinische Geräte
Butterfly Network verkauft sein tragbares Ultraschallgerät, den Butterfly iQ+, mit der folgenden Preisstruktur:
| Gerätemodell | Preis | Verkaufsvolumen (2023) |
|---|---|---|
| Butterfly iQ+ Ganzkörper | $2,999 | 15.000 Einheiten |
| Butterfly iQ+ Vet | $3,499 | 3.500 Einheiten |
Abonnementbasierte Softwaredienste
Butterfly Network bietet abgestufte Abonnements an:
| Abonnementstufe | Monatliche Kosten | Abonnenten (2023) |
|---|---|---|
| Individueller Profi | 480 $/Jahr | 8,500 |
| Enterprise Pro | 1.200 $/Jahr | 2,300 |
Unternehmenslizenzvereinbarungen
Aufschlüsselung der Unternehmenslizenzen:
- Gesamtzahl der Unternehmensverträge im Jahr 2023: 127
- Durchschnittlicher Vertragswert: 185.000 $
- Gesamtumsatz aus Unternehmenslizenzen: 23,5 Millionen US-Dollar
Klinische Forschungspartnerschaften
Einzelheiten zu den Einnahmen aus Forschungspartnerschaften:
| Partnerschaftstyp | Anzahl aktiver Partnerschaften | Generierter Umsatz |
|---|---|---|
| Akademische Forschung | 42 | 4,2 Millionen US-Dollar |
| Pharmazeutische Forschung | 18 | 7,6 Millionen US-Dollar |
Monetarisierung digitaler Gesundheitsplattformen
Einnahmequellen der Plattform:
- Cloud-Speichergebühren: 3,7 Millionen US-Dollar
- KI-Diagnoseanalyse: 2,1 Millionen US-Dollar
- Lizenzierung von Data Insights: 1,9 Millionen US-Dollar
Butterfly Network, Inc. (BFLY) - Canvas Business Model: Value Propositions
You're looking at the core reasons why a hospital system or clinician would choose Butterfly Network, Inc. (BFLY) over established cart-based ultrasound machines. It boils down to cost, portability, and now, sophisticated software integration.
The fundamental value proposition remains affordable, portable, whole-body imaging for point-of-care ultrasound (POCUS). While the specific device price point that might be too high for the EMS market-around $4,000 per unit mentioned in some commentary-is a near-term hurdle, the technology itself, powered by Ultrasound-on-Chip™, is inherently designed to be a disruptive, lower-cost alternative to traditional systems. The company achieved a record gross margin of 64% in Q2 2025, reflecting efficiency in their semiconductor-based manufacturing process.
The shift to a platform model is heavily emphasized through the AI-powered workflow software, Compass AI, which launched in November 2025. This software directly addresses administrative friction, which has historically limited the financial viability of POCUS programs. The value here is concrete:
- Documentation Agent: Cuts charting time by up to 25% using ambient voice dictation.
- Compliance Improvement: Enables documentation compliance rates up to 94%, compared to the traditional rate of only about 15% for radiology-style workflows.
- Revenue Potential: Translates that compliance into potentially five times more revenue from the same clinical volume.
This software integration also ties into direct cost reduction for health systems. Clinical publications suggest that pairing the handheld probes with Compass enterprise workflow software can help improve care workflows and reduce costs. Specifically, integrating POCUS into routine Congestive Heart Failure (CHF) management has been shown in case studies to contribute to faster discharges and an estimated ~50% cost reduction for lower-acuity patients.
The platform strategy extends outward via the Butterfly Garden, the planned AI Marketplace. Butterfly Network released its Software Development Kit (SDK) to allow third parties-AI developers, medical device companies, and telemedicine firms-to build custom applications leveraging the platform. This creates an ecosystem where new AI tools can be commercialized to Butterfly's customer base, which is described as the largest user network in handheld POCUS.
Finally, the overarching value is the democratizing access to medical imaging globally. This mission is mapped against a massive Total Addressable Market (TAM) estimated at over $350B Worldwide. The devices are commercially available to trained practitioners across numerous regions, including parts of Africa, Asia, Australia, Europe, the Middle East, North America, and South America.
Here's a quick look at the quantitative underpinning of these value propositions as of late 2025:
| Value Proposition Metric | Associated Data Point (Late 2025) |
|---|---|
| Software Documentation Time Reduction | Up to 25% cut via Documentation Agent |
| Traditional Workflow Compliance Rate | Approximately 15% of studies compliant |
| Compass AI Compliance Rate Target | Up to 94% documentation compliance |
| Potential Revenue Uplift from Compliance | As much as five times more revenue from same volume |
| Estimated Cost Reduction (Specific Use Case) | ~50% cost reduction for lower-acuity patients |
| Gross Margin (Q2 2025 Record) | 64% |
| Global TAM | $350B+ Worldwide |
The company's financial performance in 2025 shows the current reality of this mission: Q3 2025 revenue was $21.5 million, with a net loss of $13.8 million for Q2 2025. Finance: draft 13-week cash view by Friday.
Butterfly Network, Inc. (BFLY) - Canvas Business Model: Customer Relationships
The customer relationships for Butterfly Network, Inc. (BFLY) are segmented to address large institutional needs, recurring software value, and individual user enablement.
| Metric | Q3 2025 Value | Q2 2025 Value | Q1 2025 Value |
| Total Revenue | $21.5 million | $23.4 million | $21.2 million |
| Software and Other Services Revenue | $6.9 million | $6.8 million | $7.1 million |
| Software and Other Services as % of Total Revenue | N/A | 29% | N/A |
Dedicated enterprise sales and account management for large deals.
Butterfly Network, Inc. (BFLY) focuses on large-scale deployments, evidenced by closing a major enterprise-wide deal with one of the top 5 most recognized health systems in the world during Q2 2025. The company is advancing its enterprise readiness with the next-generation enterprise software, Compass AI, on track for launch before the end of 2025. Macroeconomic uncertainties caused delays in closing some large deals in U.S. hospitals and global health programs, which factored into the reaffirmed full-year 2025 revenue guidance of $91 million to $95 million.
Software subscription model for recurring, high-margin revenue.
The recurring revenue component is tied to the software and services segment, which generated $6.9 million in the third quarter of 2025. This segment represented 29% of total revenue in Q2 2025. The company noted that total Annual Recurring Revenue (ARR), reported within software and other services, grew slightly versus the prior year period, led by an increase in enterprise software subscription ARR. However, in Q3 2025, software and other services revenue was flat year-over-year, with increased licensing revenue offset by lower individual subscriptions and warranty revenue.
Self-service and educational content via Butterfly Academy and ScanLab.
Educational tools are integrated into the customer relationship to drive adoption and proficiency. The company reported specific adoption in the medical education channel:
- Kansas City University now uses the ScanLab AI-powered app across all four years of its curriculum.
- The company is advancing its formal education programs through Butterfly Academy and Butterfly Certified courses.
- A clinical validation study published in JAMA demonstrated that integrating Butterfly's Auto B-line Counter into hospitalist workflows saved an estimated $751,537 in direct costs for patients with dyspnea.
Direct-to-consumer sales for individual clinicians.
Sales to individual clinicians are part of the broader product revenue, which was $14.6 million in Q3 2025. The company is seeing a mix shift where lower individual subscriptions contributed to the flat software/services revenue performance in Q3 2025. The CEO noted that the company is building a market for the first time, suggesting a focus on acquiring individual users alongside large systems. The company also has a strategic initiative focused on the Butterfly HomeCare congestive heart failure pilot program.
Butterfly Network, Inc. (BFLY) - Canvas Business Model: Channels
You're looking at how Butterfly Network, Inc. gets its innovative ultrasound technology and software into the hands of users, which is a mix of direct selling, digital distribution, and partnerships.
The company's channel strategy relies on a segmented approach, clearly separating the US market from international efforts, and balancing hardware sales with recurring software revenue.
Here is a look at the revenue breakdown from the third quarter of 2025, which gives you a snapshot of channel performance:
| Channel Metric | Amount (Q3 2025) | Percentage of Total Revenue (Approx.) |
| Total Revenue | $21.5 million | 100% |
| US Revenue | $16.1 million | 74.9% |
| International Revenue | $5.4 million | 25.1% |
| Product Revenue | $14.6 million | 67.9% |
| Software and Other Services Revenue | $6.9 million | 32.1% |
The direct sales force targets US health systems, which accounted for $16.1 million of the $21.5 million total revenue in the third quarter of 2025. This channel is key for enterprise adoption, evidenced by signing a second top-five hospital customer in the first quarter of 2025 to integrate Compass software across approximately 600 probes and the entire network. Also, medical education adoption continues, with one-to-one student probe programs accelerating, including a leading osteopathic college purchasing a probe per incoming student in Q1 2025.
The Butterfly Garden digital platform is central to distributing the AI-powered apps. This ecosystem is growing its validated offerings:
- The portfolio expanded to 23 AI development partners as of Q2 2025.
- HeartFocus, the first FDA-cleared partner app, launched to Butterfly users in Q3 2025.
- The ScanLab AI-powered app expanded its reach in medical education, with Kansas City University using the technology across all four years of its curriculum.
- An AI-powered gestational age calculator is available in Malawi and Uganda, with FDA review underway for broader deployment.
E-commerce and direct online sales contribute to the overall product revenue, which reached $14.6 million in Q3 2025. While specific e-commerce revenue is not broken out separately from the US direct sales force, the overall US channel saw higher sales volume. To be fair, the Software and Other Services Revenue, which includes individual subscriptions, was $6.9 million in Q3 2025, representing about 32.3% of total revenue, showing a shift toward hardware sales in that quarter.
International distributors and global health partners drive the international segment, which generated $5.4 million in Q3 2025, a 4% year-over-year increase. This growth was partially attributed to the higher price point of the iQ3 probe following its international launch in the third quarter of 2024. Furthermore, the company has been delivering semiconductor chips to newly onboarded partners, as noted in Q1 2025 results, indicating expansion through strategic alliances.
Finance: review the Q4 2025 sales pipeline against the reaffirmed full-year revenue guidance of $91 million to $95 million by end of next week.
Butterfly Network, Inc. (BFLY) - Canvas Business Model: Customer Segments
You're looking at the specific groups Butterfly Network, Inc. (BFLY) targets with its diagnostic imaging and chip technology as of late 2025. It's a mix of high-volume institutional buyers and strategic technology licensees.
Large US and global health systems and hospitals represent a core segment, driving significant device and software revenue. For the second quarter of fiscal year 2025, total revenue hit a record of $23.4 million, with U.S. revenue at $17.2 million and international revenue at $6.2 million. By the third quarter of 2025, total revenue was $21.5 million, with U.S. revenue at $16.1 million and international revenue at $5.4 million. This segment is increasingly adopting the newer technology, as the iQ3 probe accounted for 85% of probe volume as of the third quarter of 2025. Furthermore, the company secured an unnamed deal in Q2 2025 with one of the top 5 most recognized health systems globally for system-wide deployment.
For medical schools and universities for student training programs, the strategy focuses on deep, long-term adoption. In the first quarter of 2025, Butterfly Network accelerated this by signing programs for a one-to-one student probe ratio, including one leading osteopathic college purchasing a probe for each incoming student. By Q3 2025, the ScanLab AI-powered educational app was being used across all four years of the curriculum at Kansas City University.
The segment of individual clinicians (e.g., emergency medicine, primary care) shows some headwinds. While product sales are strong, the software and services revenue stream saw a negative impact from lower renewals of individual subscriptions in both Q2 and Q3 2025. This suggests a shift in focus toward larger, recurring enterprise software contracts over single-user subscriptions.
Octiv partners licensing the chip technology for non-medical use is a growing, high-margin revenue driver. The sale of semiconductor chips to partners in the Octiv business contributed to the revenue growth in Q2 2025. A major development in late 2025 was the five-year co-development and licensing agreement with Midjourney, Inc., announced on November 17, 2025. This deal includes a $15 million upfront payment, an annual license fee of $10 million, and potential milestone payments up to $9 million.
For global health organizations in underserved regions, deployment is ongoing but faced external challenges; international and global health deals saw delays in Q1 2025 amid reports of USAID funding cuts. However, progress continues in specific areas, as an AI-powered gestational age calculator became available in Malawi and Uganda by Q3 2025.
Here's a quick look at the revenue segmentation based on the Q2 2025 data, which shows the relative contribution of the product versus services/licensing components of the customer base:
| Customer Revenue Component | Q2 2025 Amount | Q3 2025 Amount |
| Total Revenue | $23.4 million | $21.5 million |
| Product Revenue | $16.6 million | $14.6 million |
| Software and Other Services Revenue | $6.8 million | $6.9 million |
| Octiv Chip Sales Impact (Included in Product Revenue) | Significant Driver | Implied in Product Revenue |
The company is definitely seeing a mix of institutional adoption and strategic platform licensing. If onboarding for those large enterprise deals takes longer than expected, cash burn management becomes even more critical.
The customer base can be summarized by their primary interaction with Butterfly Network, Inc. (BFLY):
- Acquire the full imaging system (iQ3/iQ+).
- Subscribe to enterprise workflow software (Compass).
- License the core Ultrasound-on-Chip technology.
- Purchase probes per student for educational use.
- Utilize specialized apps like the AI-powered gestational age calculator.
Finance: draft 13-week cash view by Friday.
Butterfly Network, Inc. (BFLY) - Canvas Business Model: Cost Structure
You're looking at the costs that drive Butterfly Network, Inc. (BFLY)'s operations as of late 2025. The structure shows significant investment in future technology alongside the cost of delivering current hardware and services.
High Research and Development (R&D) expenses for chip and AI innovation are embedded within the total operating spend. The company is pushing forward on technology milestones, including the P5 chip and fourth-generation technology, alongside the launch of Compass AI software. Total operating expenses for the third quarter ended September 30, 2025, reached $31.4 million, which was up 6% from $29.5 million in the prior year period.
Sales, General, and Administrative (SG&A) costs for enterprise expansion are also part of this operating structure. The company is focused on strengthening enterprise readiness. When looking at the core operating spend, total operating expenses excluding stock-based compensation and other expenses were $23.7 million for Q3 2025, compared to $23.4 million in the prior year period. This suggests a relatively flat core operational spend year-over-year, despite the enterprise focus.
Cost of Goods Sold (COGS), including manufacturing and inventory, saw a major non-recurring impact in Q3 2025. The underlying adjusted gross margin improved, but the GAAP figures were heavily skewed by inventory charges. The adjusted gross margin for Q3 2025 was 63.9%, up from 60.0% in the prior year period, resulting in an adjusted gross profit of $13.7 million.
The impact on GAAP COGS is clear from the write-down. The cost of product revenue specifically soared by 288.3% to $25.24 million in Q3 2025, largely due to the inventory charge. Conversely, the cost of software and services revenue decreased by 25.1%, attributed to lower amortization expenses.
Non-cash charge for inventory write-down of $17.4 million in Q3 2025 is the most significant single cost event impacting the reported financials. This charge was for excess and obsolete inventory and is excluded from adjusted gross profit and adjusted gross margin calculations. This write-down drove the GAAP gross margin to (17.5)% for the quarter, compared to 59.5% in the prior year period.
Here is a look at the key Q3 2025 cost and expense figures:
| Cost/Expense Category | Q3 2025 Amount (USD Millions) | Comparison/Context |
| Total Operating Expenses | $31.4 | Up 6% year-over-year from $29.5 million |
| Operating Expenses (Ex-Stock Comp/Other) | $23.7 | Essentially flat to $23.4 million in the prior year period |
| Inventory Write-Down (Non-Cash Charge) | $17.4 | Recognized in Q3 2025; excluded from Adjusted Gross Profit |
| Cost of Product Revenue | $25.24 | Increased by 288.3% due to inventory charge |
| Adjusted Gross Profit | $13.7 | Up from $12.3 million in the prior year period |
The company's overall financial performance in Q3 2025 reflected these costs, leading to a reported net loss of $34.0 million, compared to $16.9 million in the prior year period. The cash position, however, remained a focus, with cash and cash equivalents at $144.2 million as of September 30, 2025.
Key components driving the operating expenses include:
- Advancing AI development and technology milestones.
- Costs associated with strengthening enterprise readiness.
- Costs related to the launch of Compass AI.
- Manufacturing and supply chain costs for hardware units.
The company is managing its cash burn, reducing its quarterly cash burn to $3.9 million in Q3 2025, a new record low for quarterly cash usage.
Finance: draft 13-week cash view by Friday.Butterfly Network, Inc. (BFLY) - Canvas Business Model: Revenue Streams
You're looking at how Butterfly Network, Inc. (BFLY) is bringing in cash as of late 2025. The business model clearly relies on a mix of hardware sales, recurring software revenue, and now, significant technology licensing income.
For the full fiscal year 2025, Butterfly Network, Inc. reaffirmed its revenue guidance to be in the range of $91 million and $95 million, which represents approximately 13% growth year-over-year.
Here's a look at the component parts of revenue based on recent performance metrics. The Q2 2025 results showed strong product revenue growth outpacing software, but the licensing component is now a major factor.
| Revenue Component | Q2 2025 Amount | Q3 2025 Amount (as specified) |
| Product Revenue (iQ3 sales) | $16.6 million | $14.6 million |
| Software and Other Services Revenue | $6.8 million | Not specified |
| Total Reported Quarterly Revenue | $23.4 million | $21.5 million |
Product Revenue from the sale of the iQ3 probe and related hardware remains a core stream. For the third quarter of 2025, this component was reported at $14.6 million. This contrasts with the second quarter of 2025, where product revenue reached $16.6 million, marking a 13% increase versus Q2 2024, partly due to higher average selling prices and chip sales to partners in the Octiv business.
Software and Other Services Revenue, which includes subscriptions, is the recurring element of the model. In the second quarter of 2025, this stream brought in $6.8 million, which was flat compared to the prior year period, despite an increase in enterprise software subscription Annual Recurring Revenue (ARR).
Technology licensing revenue has recently become a material component, highlighted by a major agreement.
- Butterfly Network, Inc. entered a five-year, exclusive co-development and licensing agreement with Midjourney on November 17, 2025.
- This deal includes an upfront, non-recurring fee of $15 million.
- It secures an ongoing $10 million annual license fee, which is paid quarterly over the five-year term.
- The agreement also allows for up to $9 million in additional milestone payments.
- Butterfly Network, Inc. is also eligible for revenue sharing and payments for chip purchases made by Midjourney.
The Octiv business was also noted as a contributor to Q2 2025 revenue through the sale of semiconductor chips to partners.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.